JP2015509788A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509788A5
JP2015509788A5 JP2014560032A JP2014560032A JP2015509788A5 JP 2015509788 A5 JP2015509788 A5 JP 2015509788A5 JP 2014560032 A JP2014560032 A JP 2014560032A JP 2014560032 A JP2014560032 A JP 2014560032A JP 2015509788 A5 JP2015509788 A5 JP 2015509788A5
Authority
JP
Japan
Prior art keywords
dry powder
processable
respirable
sodium
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014560032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028261 external-priority patent/WO2013130767A1/en
Publication of JP2015509788A publication Critical patent/JP2015509788A/ja
Publication of JP2015509788A5 publication Critical patent/JP2015509788A5/ja
Pending legal-status Critical Current

Links

JP2014560032A 2012-02-29 2013-02-28 吸入に適した乾燥粉末 Pending JP2015509788A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261605083P 2012-02-29 2012-02-29
US61/605,083 2012-02-29
US201261607928P 2012-03-07 2012-03-07
US61/607,928 2012-03-07
US201261645927P 2012-05-11 2012-05-11
US61/645,927 2012-05-11
US201261648506P 2012-05-17 2012-05-17
US61/648,506 2012-05-17
US201261707071P 2012-09-28 2012-09-28
US61/707,071 2012-09-28
PCT/US2013/028261 WO2013130767A1 (en) 2012-02-29 2013-02-28 Inhalable dry powders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017104816A Division JP2017140515A (ja) 2012-02-29 2017-05-26 吸入に適した乾燥粉末

Publications (2)

Publication Number Publication Date
JP2015509788A JP2015509788A (ja) 2015-04-02
JP2015509788A5 true JP2015509788A5 (enExample) 2016-04-14

Family

ID=47884560

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014560032A Pending JP2015509788A (ja) 2012-02-29 2013-02-28 吸入に適した乾燥粉末
JP2017104816A Pending JP2017140515A (ja) 2012-02-29 2017-05-26 吸入に適した乾燥粉末
JP2019128556A Pending JP2019181244A (ja) 2012-02-29 2019-07-10 吸入に適した乾燥粉末

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017104816A Pending JP2017140515A (ja) 2012-02-29 2017-05-26 吸入に適した乾燥粉末
JP2019128556A Pending JP2019181244A (ja) 2012-02-29 2019-07-10 吸入に適した乾燥粉末

Country Status (9)

Country Link
US (4) US20150136130A1 (enExample)
EP (1) EP2819672A1 (enExample)
JP (3) JP2015509788A (enExample)
CN (3) CN107596518B (enExample)
AU (1) AU2013225982B2 (enExample)
CA (1) CA2865972C (enExample)
HK (1) HK1204989A1 (enExample)
NZ (1) NZ629722A (enExample)
WO (1) WO2013130767A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
EP4008326A1 (en) * 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
SE1150190A1 (sv) 2011-03-02 2012-06-19 Climatewell Ab Publ Salt överdraget med nanopartiklar
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
BR112017023351B1 (pt) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
MX2017016686A (es) * 2015-07-13 2018-03-26 Philip Morris Products Sa Produccion de una composicion formadora de aerosol.
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
IL260823B2 (en) * 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
CA3023626A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles
JP6581308B2 (ja) * 2016-10-17 2019-09-25 一般社団法人 金沢大整形 癌治療剤
DE102017006763A1 (de) * 2017-07-18 2019-01-24 Klaus Dieter Beller Einzeldosis-Pulverinhalator
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
EP3691646A4 (en) * 2017-10-02 2021-06-30 Board of Regents, The University of Texas System CLOFAZIMIN INHALABLE COMPOSITION AND METHOD OF USE
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
KR20250042852A (ko) 2018-01-12 2025-03-27 (주) 메티메디제약 만성 염증성 질환의 치료 방법
RU2020127882A (ru) * 2018-01-26 2022-02-28 Новартис Аг Доставка высоких доз ингаляционных терапевтических средств
KR20200125632A (ko) * 2018-02-26 2020-11-04 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 분말 제제, 카트리지 및 디바이스
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
KR20210014629A (ko) * 2018-04-18 2021-02-09 시플라 테크놀로지스 엘엘씨 진균 감염의 치료방법
WO2019204583A1 (en) * 2018-04-18 2019-10-24 Pulmatrix Operating Company, Inc. Antifungal formulations for pulmonary administration comprising itraconazole
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
CN109089882B (zh) * 2018-08-30 2022-02-08 云南省农业科学院花卉研究所 一种通过孢子直接诱导的苔藓组培及成苗培养方法
US12337064B2 (en) 2018-09-05 2025-06-24 Sensory Cloud, Inc. Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
US20200170280A1 (en) * 2018-11-30 2020-06-04 Balchem Corporation Metal complex or metal chelate compositions comprising minimal nanoparticles
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
EP3990472A4 (en) 2019-06-26 2023-07-12 The University of Southern California Compositions and methods for treatment of fungal infections
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
CN121221570A (zh) * 2019-11-06 2025-12-30 曼金德公司 氯法齐明的组合物,含它们的组合,它们的制备方法,含它们的用途和治疗方法
CN111358773B (zh) * 2020-04-10 2021-03-30 广州南鑫药业有限公司 一种帕拉米韦干粉吸入剂及其制备方法
US12329727B2 (en) 2020-04-24 2025-06-17 The Medical College Of Wisconsin, Inc. Use of salmeterol as an anti-coronaviral agent
CN115835885B (zh) * 2020-06-23 2025-02-07 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び/又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
CN111690073B (zh) * 2020-07-27 2021-11-26 西华师范大学 一种绒白乳菇多糖及其制备方法和应用
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
WO2022081814A1 (en) * 2020-10-16 2022-04-21 Michael Ogburn Inhalable cannabinoid formulations
CA3197627A1 (en) * 2020-11-18 2022-05-27 Kimberly SHEPARD Inhalable dry powder formulations comprising angiogenesis inhibitors
WO2022187222A1 (en) * 2021-03-03 2022-09-09 Pulmatrix Operating Company, Inc. Dihydroergotamine dry power formulations and methods of use
CA3226155A1 (en) * 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
CN114846943B (zh) * 2022-06-10 2023-04-11 湖南亿恒环保工程有限公司 一种防止土壤酸化的土壤改良方法
EP4626438A2 (en) * 2022-12-01 2025-10-08 Pinata Holdings Inc. Inhalable hormone receptor agonist formulations
WO2025004049A1 (en) * 2023-06-28 2025-01-02 Sheba Impact Ltd. Treatment of infections caused by intracellular pathogens
KR20250068882A (ko) * 2023-11-10 2025-05-19 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 건조 분말 흡입 제형 및 이의 제조방법

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE3229179C2 (de) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4637815A (en) 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5571535A (en) 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
JPH05123398A (ja) 1991-11-06 1993-05-21 Tsunemasa Kamiyama 咽喉保護吸入剤並びに吸入器具
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
NZ328476A (en) 1993-06-24 1999-05-28 Astra Ab Use of a two component insulin preparation in an inhalation device
FR2714782B1 (fr) 1993-12-30 1996-02-02 Alcatel Telspace Estimateur en bande de base de la caractéristique amplitude/fréquence d'un signal à pluralités de phases.
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5468680A (en) 1994-03-18 1995-11-21 Massachusetts Institute Of Technology Method of making a three-terminal fuse
US5633003A (en) 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CA2202623A1 (en) 1994-10-14 1996-04-25 Hitoshi Nagaoka Azole derivative
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6264854B1 (en) 1995-09-07 2001-07-24 Claude Q. C. Hayes Heat absorbing temperature control devices and method
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5863084A (en) 1997-12-04 1999-01-26 Krug; Richard D. Lifting aid device for a shovel
EP1067839A1 (en) 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
FR2780285B1 (fr) 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
JP2002521423A (ja) 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
EP1121047A1 (en) 1998-09-09 2001-08-08 U.S. Army Institute of Surgical Research Pulse oximeter sensor combined with oropharyngeal airway and bite block
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
MXPA01011283A (es) 1999-05-03 2002-11-04 Battelle Memorial Institute Composiciones par aerosolizacion e inhalacion.
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
DE60017152D1 (de) 1999-08-25 2005-02-03 Advanced Inhalation Res Inc Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
NO314053B1 (no) 1999-12-28 2003-01-20 Norske Stats Oljeselskap Momentkobling for bruk i borestreng
EP1246608A4 (en) 2000-01-05 2005-05-18 Imarx Therapeutics Inc PHARMACEUTICAL FORMULATIONS FOR THE ADMINISTRATION OF MEDICAMENTS HAVING A LOW AQUEOUS SOLUBILITY
AUPQ544900A0 (en) 2000-02-04 2000-02-24 Commonwealth Scientific And Industrial Research Organisation Treatment of cellulosic material
AU772096B2 (en) 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6564108B1 (en) 2000-06-07 2003-05-13 The Delfin Project, Inc. Method and system of auxiliary illumination for enhancing a scene during a multimedia presentation
ES2292598T3 (es) 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
AU2001278131A1 (en) 2000-08-01 2002-02-13 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6572849B2 (en) 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
EP2283817B1 (en) 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
DK2301524T3 (da) 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
PT1416917E (pt) 2001-08-06 2007-08-16 Astrazeneca Ab ''dispersão aquosa compreendendo nanopartículas estáveis de um triglicérido de cadeia média (mct) activo insolúvel em água e um do tipo excipiente''
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
JP2005509052A (ja) 2001-10-23 2005-04-07 インノゲル アクチエンゲゼルシャフト 多糖類を基剤とする網状構造およびその製造方法
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
IL161446A0 (en) 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
SI2630954T1 (sl) 2002-03-20 2017-02-28 Civitas Therapeutics, Inc. Pulmonalno dovajanje za levodopo
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
CA2483687A1 (en) 2002-05-13 2003-11-20 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US20030228972A1 (en) 2002-06-05 2003-12-11 Birss Viola Oxygen reduction catalyst
EP1511467A1 (en) 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP1531794B1 (en) 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Inhalable epinephrine
US20050288253A1 (en) 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
AU2003205543A1 (en) 2003-01-14 2004-08-10 Lifecycle Pharma A/S Dry dispersions
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1194062C (zh) 2003-04-04 2005-03-23 王泽斌 一种融雪融冰组合物及其制备方法和应用
SI1617834T1 (sl) 2003-05-01 2007-02-28 Innogene Kalbiotech Pte Ltd Uporaba farmacevtskega sestavka, ki vsebuje mlecno kislino ali laktat in kalij, za zdravljenje mozganskega edema in mozganske poskodbe
EP1646370A1 (en) 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0322358D0 (en) 2003-09-24 2003-10-22 Bioprogress Technology Ltd Improvements in powder compaction and enrobing
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
KR20050056622A (ko) 2003-12-10 2005-06-16 주식회사 대우일렉트로닉스 플레쉬롬 다운로드 장치
WO2005067898A2 (en) 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
CA2602596A1 (en) 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
WO2006038070A2 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
ES2317259T3 (es) 2004-06-29 2009-04-16 Jado Technologies Gmbh Esfingolipidos contra procesos patologicos en baldas lipidicas.
DE102004031863B3 (de) 2004-07-01 2006-03-09 Airbus Deutschland Gmbh Vorrichtung zur Fixierung von insbesondere flächenhaften Werkstücken mit einer Anlagefläche
CA2574958A1 (en) 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20060073173A1 (en) 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2006102438A2 (en) 2005-03-23 2006-09-28 Ihc Intellectual Asset Management, Llc Methods and compositions for irrigation of mucosal tissues
WO2006125153A2 (en) 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
HUE030419T2 (en) 2005-05-18 2017-05-29 Horizon Orphan Llc Aerosolized fluoroquinolones and their uses
US7336883B2 (en) 2005-09-08 2008-02-26 Stratos International, Inc. Indexing optical fiber adapter
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
GB0523576D0 (en) 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
KR100743181B1 (ko) 2006-07-29 2007-07-27 주식회사 메가젠 치과용 응급 임플란트의 내부결합형 픽스츄어
EP1894865A1 (de) 2006-08-31 2008-03-05 Claudius Peters Technologies GmbH Fördervorrichtung für pulverförmiges Gut
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
US20100099756A1 (en) 2006-11-29 2010-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Uses of incensole, incensole acetate and derivatives thereof
US8501255B2 (en) 2006-12-14 2013-08-06 Purac Biochem B.V. Particulate composition comprising calcium lactate and calcium citrate microparticles
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
JP5399232B2 (ja) 2007-02-21 2014-01-29 富士通セミコンダクター株式会社 半導体装置の製造方法
EP2011495A1 (en) 2007-07-03 2009-01-07 Sygnis Bioscience GmbH & Co. KG Use of piperine and derivatives thereof for the therapy of neurological conditions
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
US8461145B2 (en) 2007-12-05 2013-06-11 Janssen Pharmaceutica Nv Dibenzoazepine and dibenzooxazepine TRPA1 agonists
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US8834930B2 (en) 2008-05-15 2014-09-16 Novartis Ag Pulmonary delivery of a fluoroquinolone
EP2323640A2 (en) 2008-08-04 2011-05-25 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
GB0818476D0 (en) 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
RU2505306C2 (ru) 2008-12-12 2014-01-27 Георгиос ПАНДАЛИС Композиция для профилактики и лечения вирусных инфекций
WO2010080754A2 (en) 2009-01-06 2010-07-15 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
KR20120015295A (ko) 2009-03-26 2012-02-21 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
EP2410984A2 (en) 2009-03-26 2012-02-01 Pulmatrix, Inc. Anti-influenza formulations and methods
AU2010229721A1 (en) 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
PT2315580E (pt) 2009-03-26 2012-03-28 Pulmatrix Inc Formulações farmacêuticas e métodos para o tratamento de infeções do trato respiratório
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US9433588B2 (en) 2009-11-09 2016-09-06 Virginia Commonwealth Univeristy Delivery of submicrometer and nanometer aerosols to the lungs using hygroscopic excipients or dual stream nasal delivery
CN103249328A (zh) 2010-08-30 2013-08-14 本杰明.王 人体结构自适应且符合人体工学的负载分布带
WO2012030664A1 (en) * 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP4008326A1 (en) * 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada

Similar Documents

Publication Publication Date Title
ES2708218T3 (es) Método y formulación para inhalación
JP2016065107A5 (enExample)
JP2013536845A5 (enExample)
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
JP2011116788A5 (enExample)
Miranda et al. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery
JP2012176990A5 (enExample)
JP2016534153A5 (enExample)
JP2013540123A5 (enExample)
JP2013509429A5 (enExample)
JP2015527402A5 (enExample)
JP2014240439A5 (enExample)
NZ708684A (en) High dose levodopa capsules for pulmonary use
JP2012255026A5 (enExample)
JP2013508344A5 (enExample)
HRP20240197T1 (hr) Farmaceutski pripravak koji sadrži protuvirusni derivat dihidrokinazolina koji ima konfiguraciju s na položaju 4
JP2016539921A5 (enExample)
RU2018120519A (ru) Фармацевтические композиции рибавирина
JP2016510326A5 (enExample)
JP2019517541A5 (enExample)
HRP20160802T1 (hr) Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka
JP2015515968A5 (enExample)
JP2017105861A5 (enExample)
RS53784B2 (sr) Inhalacioni lek koji obuhvata amorfni tiotropijum bromid
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu